Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 271

1.

Exploring HIV-1 Transmission Dynamics by Combining Phylogenetic Analysis and Infection Timing.

Verhofstede C, Mortier V, Dauwe K, Callens S, Deblonde J, Dessilly G, Delforge ML, Fransen K, Sasse A, Stoffels K, Van Beckhoven D, Vanroye F, Vaira D, Vancutsem E, Van Laethem K.

Viruses. 2019 Nov 26;11(12). pii: E1096. doi: 10.3390/v11121096.

2.

Insights on Multiple Myeloma Treatment Strategies.

Mateos MV, Ludwig H, Bazarbachi A, Beksac M, Bladé J, Boccadoro M, Cavo M, Delforge M, Dimopoulos MA, Facon T, Geraldes C, Goldschmidt H, Hájek R, Hansson M, Jamroziak K, Leiba M, Masszi T, Mendeleeva L, O'Dwyer M, Plesner T, San-Miguel JF, Straka C, van de Donk NWCJ, Yong K, Zver S, Moreau P, Sonneveld P.

Hemasphere. 2018 Dec 27;3(1):e163. doi: 10.1097/HS9.0000000000000163. eCollection 2019 Feb. Review.

3.

Carfilzomib-induced reticulocytosis in patients with multiple myeloma is caused by impaired terminal erythroid maturation.

Kint NG, Heylen E, Pepe D, De Keersmaecker K, Verfaillie CM, Delforge M.

Leukemia. 2019 Aug 29. doi: 10.1038/s41375-019-0565-y. [Epub ahead of print] No abstract available.

PMID:
31467428
4.

High rate of rubella seronegativity in perinatally-infected HIV women of childbearing age: A case-control study.

Beun AJ, Grammens T, Hainaut M, Barlow P, Van den Wijngaert S, Delforge M, De Wit S, Dauby N.

Vaccine. 2019 Sep 20;37(40):5930-5933. doi: 10.1016/j.vaccine.2019.08.034. Epub 2019 Aug 23.

PMID:
31451323
5.

Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network.

Moreau P, Sonneveld P, Boccadoro M, Cook G, Mateos MV, Nahi H, Goldschmidt H, Dimopoulos MA, Lucio P, Bladé J, Delforge M, Hajek R, Ludwig H, Facon T, Miguel JFS, Einsele H.

Haematologica. 2019 Dec;104(12):2358-2360. doi: 10.3324/haematol.2019.224204. Epub 2019 Aug 22.

6.

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.

Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kaminetzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin JR, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG, Jagannath S.

N Engl J Med. 2019 Aug 22;381(8):727-738. doi: 10.1056/NEJMoa1903455.

PMID:
31433920
7.

Comparison of IVIg 5% Versus 10% in hematological patients with a secondary immunodeficiency disorder.

Van Ham J, Janssens A, Raddoux J, Raets E, Delforge M.

Acta Clin Belg. 2019 Aug 17:1-4. doi: 10.1080/17843286.2019.1655860. [Epub ahead of print]

PMID:
31422766
8.

Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma.

Hájek R, Delforge M, Raab MS, Schoen P, DeCosta L, Spicka I, Radocha J, Pour L, Gonzalez-McQuire S, Bouwmeester W.

Br J Haematol. 2019 Nov;187(4):447-458. doi: 10.1111/bjh.16105. Epub 2019 Aug 6.

PMID:
31388996
9.

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.

Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, Béné MC, Broijl A, Caillon H, Caillot D, Corre J, Delforge M, Dejoie T, Doyen C, Facon T, Sonntag C, Fontan J, Garderet L, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Lenain P, Macro M, Mathiot C, Orsini-Piocelle F, Perrot A, Stoppa AM, van de Donk NW, Wuilleme S, Zweegman S, Kolb B, Touzeau C, Roussel M, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Fermand JP, Escoffre-Barbe M, Eveillard JR, Garidi R, Ahmadi T, Zhuang S, Chiu C, Pei L, de Boer C, Smith E, Deraedt W, Kampfenkel T, Schecter J, Vermeulen J, Avet-Loiseau H, Sonneveld P.

Lancet. 2019 Jul 6;394(10192):29-38. doi: 10.1016/S0140-6736(19)31240-1. Epub 2019 Jun 3. Erratum in: Lancet. 2019 Jun 14;:.

PMID:
31171419
10.

Combining conventional therapy with immunotherapy: A risky business?

Coosemans A, Vankerckhoven A, Baert T, Boon L, Ruts H, Riva M, Blagden S, Delforge M, Concin N, Mirza MR, Ledermann JA, du Bois A, Vergote I.

Eur J Cancer. 2019 May;113:41-44. doi: 10.1016/j.ejca.2019.02.014. Epub 2019 Apr 6.

PMID:
30965214
11.

Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis.

Demuynck T, Verhoef G, Delforge M, Vandenberghe P, Devos T.

Ann Hematol. 2019 Jun;98(6):1421-1426. doi: 10.1007/s00277-019-03654-6. Epub 2019 Mar 27.

PMID:
30919072
12.

Velocities of Naturally Occurring Myocardial Shear Waves Increase With Age and in Cardiac Amyloidosis.

Petrescu A, Santos P, Orlowska M, Pedrosa J, Bézy S, Chakraborty B, Cvijic M, Dobrovie M, Delforge M, D'hooge J, Voigt JU.

JACC Cardiovasc Imaging. 2019 Dec;12(12):2389-2398. doi: 10.1016/j.jcmg.2018.11.029. Epub 2019 Feb 13.

PMID:
30772218
13.

Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practice.

Hulin C, de la Rubia J, Dimopoulos MA, Terpos E, Katodritou E, Hungria V, De Samblanx H, Stoppa AM, Aagesen J, Sargin D, Sioni A, Belch A, Diels J, Olie RA, Robinson D Jr, Potamianou A, van de Velde H, Delforge M.

Health Sci Rep. 2018 Dec 7;2(1):e104. doi: 10.1002/hsr2.104. eCollection 2019 Jan.

14.

Epidemiology and clinical management of HIV-HBV coinfected patients in a large AIDS Reference Center in Belgium.

Farid Y, Martin C, Delforge M, De Wit S.

Acta Clin Belg. 2019 Dec;74(6):424-429. doi: 10.1080/17843286.2018.1554292. Epub 2018 Dec 4.

PMID:
30513065
15.

Correction to: Biological tests carried out on serum/plasma samples from donors of human body material for transplantation: Belgian experience and practical recommendations.

Padalko E, Lagrou K, Delforge ML, Jansens H, Ectors N, Pirnay JP, Klykens J, Sokal E, Muylle L, Libois A, Vanderkelen A, Verbeken G, Matthys C, Goossens D, Hanssens G, Baltes M, Beele H.

Cell Tissue Bank. 2018 Dec;19(4):835-836. doi: 10.1007/s10561-018-9728-8.

16.

Combination of line immunoassays Mikrogen recomLine CMV IgG and recomLine CMV IgG Avidity helps to date the onset of CMV primary infection.

Delforge ML, Eykmans J, Steensels D, Costa E, Donner C, Montesinos I.

Diagn Microbiol Infect Dis. 2019 Mar;93(3):208-212. doi: 10.1016/j.diagmicrobio.2018.09.013. Epub 2018 Oct 4.

PMID:
30361044
17.

Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial.

van de Donk NW, van der Holt B, Minnema MC, Vellenga E, Croockewit S, Kersten MJ, von dem Borne PA, Ypma P, Schaafsma R, de Weerdt O, Klein SK, Delforge M, Levin MD, Bos GM, Jie KG, Sinnige H, Coenen JL, de Waal EG, Zweegman S, Sonneveld P, Lokhorst HM.

Lancet Haematol. 2018 Oct;5(10):e479-e492. doi: 10.1016/S2352-3026(18)30149-2.

PMID:
30290905
18.

European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when.

Caers J, Garderet L, Kortüm KM, O'Dwyer ME, van de Donk NWCJ, Binder M, Dold SM, Gay F, Corre J, Beguin Y, Ludwig H, Larocca A, Driessen C, Dimopoulos MA, Boccadoro M, Gramatzki M, Zweegman S, Einsele H, Cavo M, Goldschmidt H, Sonneveld P, Delforge M, Auner HW, Terpos E, Engelhardt M.

Haematologica. 2018 Nov;103(11):1772-1784. doi: 10.3324/haematol.2018.189159. Epub 2018 Aug 31. Review.

19.

Biological tests carried out on serum/plasma samples from donors of human body material for transplantation: Belgian experience and practical recommendations.

Padalko E, Lagrou K, Delforge ML, Jansens H, Ectors N, Pirnay JP, Klykens J, Sokal E, Muylle L, Libois A, Vanderkelen A, Verbeken G, Matthys C, Goossens D, Hanssens G, Baltes M, Beele H.

Cell Tissue Bank. 2018 Dec;19(4):681-695. doi: 10.1007/s10561-018-9721-2. Epub 2018 Aug 29. Erratum in: Cell Tissue Bank. 2018 Oct 26;:.

20.

Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice.

Terpos E, Katodritou E, de la Rubia J, Hungria V, Hulin C, Roussou M, Delforge M, Bries G, Stoppa AM, Aagesen J, Sargin D, Belch A, Ahlberg L, Diels J, Olie RA, Robinson D Jr, Spencer M, Potamianou A, van de Velde H, Dimopoulos MA.

Eur J Haematol. 2018 Oct;101(4):556-565. doi: 10.1111/ejh.13147. Epub 2018 Sep 5.

PMID:
30027641
21.

Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients.

Jurczyszyn A, Castillo JJ, Avivi I, Czepiel J, Davila J, Vij R, Fiala MA, Gozzetti A, Grząśko N, Milunovic V, Hus I, Mądry K, Waszczuk-Gajda A, Usnarska-Zubkiewicz L, Dębski J, Atilla E, Beksac M, Mele G, Sawicki W, Jayabalan D, Charliński G, Gyula Szabo A, Hajek R, Delforge M, Kopacz A, Fantl D, Waage A, Crusoe E, Hungria V, Richardson P, Laubach J, Guerrero-Garcia T, Liu J, Vesole DH.

Leuk Lymphoma. 2019 Jan;60(1):118-123. doi: 10.1080/10428194.2018.1473574. Epub 2018 Jul 2.

PMID:
29965787
22.

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.

Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos MA, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos MV, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk NWCJ, Waage A, Beksac M, Mellqvist UH, Engelhardt M, Caers J, Driessen C, Bladé J, Sonneveld P.

Leukemia. 2018 Jul;32(7):1542-1560. doi: 10.1038/s41375-018-0040-1. Epub 2018 May 2. Review.

23.

Long-term treatment with atazanavir (ATV) in real life in Belgium: a retrospective observational cohort of 2264 HIV patients.

De Wit S, Florence E, Vandekerkhove L, Goffard JC, Vandercam B, Van Wijngaerden E, Moutschen M, Demeester R, Lacor P, Delforge M, van Frankenhuijsen M, Lacante P.

Acta Clin Belg. 2019 Jun;74(3):143-150. doi: 10.1080/17843286.2018.1462753. Epub 2018 May 2.

PMID:
29718781
24.

Prevalence of Mycoplasma genitalium in men with urethritis in a large public hospital in Brussels, Belgium: An observational, cross-sectional study.

Libois A, Hallin M, Crucitti T, Delforge M, De Wit S.

PLoS One. 2018 Apr 26;13(4):e0196217. doi: 10.1371/journal.pone.0196217. eCollection 2018.

25.

Antigen excess detection by automated assays for free light chains.

Bossuyt X, Delforge M, Reynders M, Dillaerts D, Sprangers B, Fostier K, Poesen K, Vercammen M.

Clin Chem Lab Med. 2018 Aug 28;56(9):e235-e238. doi: 10.1515/cclm-2017-0977. No abstract available.

PMID:
29679525
26.

Diagnostic thresholds for free light chains in multiple myeloma depend on the assay used.

Bossuyt X, Delforge M, Reynders M, Dillaerts D, Sprangers B, Fostier K, Poesen K, Vercammen M.

Leukemia. 2018 Aug;32(8):1815-1818. doi: 10.1038/s41375-018-0041-0. Epub 2018 Apr 20. No abstract available.

PMID:
29674643
27.

Prevalence and risk factors of measles seronegativity in a cohort of HIV-positive subjects: a retrospective study.

Dauby N, Martin C, Hainaut M, Grammens T, Van den Wijngaert S, Delforge M, De Wit S.

HIV Med. 2018 Jul;19(6):426-429. doi: 10.1111/hiv.12610. Epub 2018 Mar 24.

PMID:
29573535
28.

Phylogenetic analysis of the Belgian HIV-1 epidemic reveals that local transmission is almost exclusively driven by men having sex with men despite presence of large African migrant communities.

Verhofstede C, Dauwe K, Fransen K, Van Laethem K, Van den Wijngaert S, Ruelle J, Delforge ML, Vancutsem E, Vaira D, Stoffels K, Ribas SG, Dessilly G, Debaisieux L, Pierard D, Van Ranst M, Hayette MP, Deblonde J, Sasse A, Van Beckhoven D, Mortier V.

Infect Genet Evol. 2018 Jul;61:36-44. doi: 10.1016/j.meegid.2018.03.002. Epub 2018 Mar 6.

29.

Screening for Chlamydia trachomatis and Neisseria gonorrhoeae Infections in Men Who Have Sex With Men: Diagnostic Accuracy of Nucleic Acid Amplification Test on Pooled Urine, Anorectal, and Pharyngeal Specimens.

Thielemans E, Wyndham-Thomas C, Henrard S, De Vleeschouwer A, Steensels D, Montesinos I, Debaisieux L, Delforge ML, Van Vooren JP, Goffard JC.

Sex Transm Dis. 2018 Mar;45(3):195-198. doi: 10.1097/OLQ.0000000000000722.

PMID:
29419710
30.

Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT.

Gagelmann N, Eikema DJ, Iacobelli S, Koster L, Nahi H, Stoppa AM, Masszi T, Caillot D, Lenhoff S, Udvardy M, Crawley C, Arcese W, Mariette C, Hunter A, Leleu X, Schipperus M, Delforge M, Pioltelli P, Snowden JA, Itälä-Remes M, Musso M, van Biezen A, Garderet L, Kröger N.

Haematologica. 2018 May;103(5):890-897. doi: 10.3324/haematol.2017.178434. Epub 2018 Feb 1.

31.

Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes.

Neggers JE, Kwanten B, Dierckx T, Noguchi H, Voet A, Bral L, Minner K, Massant B, Kint N, Delforge M, Vercruysse T, Baloglu E, Senapedis W, Jacquemyn M, Daelemans D.

Nat Commun. 2018 Feb 5;9(1):502. doi: 10.1038/s41467-017-02349-8.

32.

Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel.

Caers J, Paiva B, Zamagni E, Leleu X, Bladé J, Kristinsson SY, Touzeau C, Abildgaard N, Terpos E, Heusschen R, Ocio E, Delforge M, Sezer O, Beksac M, Ludwig H, Merlini G, Moreau P, Zweegman S, Engelhardt M, Rosiñol L.

J Hematol Oncol. 2018 Jan 16;11(1):10. doi: 10.1186/s13045-017-0549-1. Review.

33.

Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients.

Jurczyszyn A, Radocha J, Davila J, Fiala MA, Gozzetti A, Grząśko N, Robak P, Hus I, Waszczuk-Gajda A, Guzicka-Kazimierczak R, Atilla E, Mele G, Sawicki W, Jayabalan DS, Charliński G, Szabo AG, Hajek R, Delforge M, Kopacz A, Fantl D, Waage A, Avivi I, Rodzaj M, Leleu X, Richez V, Knopińska-Posłuszny W, Masternak A, Yee AJ, Barchnicka A, Druzd-Sitek A, Guerrero-Garcia T, Liu J, Vesole DH, Castillo JJ.

Br J Haematol. 2018 Mar;180(6):831-839. doi: 10.1111/bjh.15092. Epub 2018 Jan 7.

PMID:
29315478
34.

Meropenem-clavulanate for drug-resistant tuberculosis: a follow-up of relapse-free cases.

Payen MC, Muylle I, Vandenberg O, Mathys V, Delforge M, Van den Wijngaert S, Clumeck N, De Wit S.

Int J Tuberc Lung Dis. 2018 Jan 1;22(1):34-39. doi: 10.5588/ijtld.17.0352.

PMID:
29297423
35.

Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate?

Leleu X, Gay F, Flament A, Allcott K, Delforge M.

Ann Hematol. 2018 Mar;97(3):387-400. doi: 10.1007/s00277-017-3191-7. Epub 2017 Dec 27. Review.

36.

Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network.

Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos MA, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos MV, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk NWCJ, Waage A, Beksac M, Mellqvist UH, Engelhardt M, Caers J, Driessen C, Sonneveld P.

Leukemia. 2017 Dec 18. doi: 10.1038/leu.2017.353. [Epub ahead of print] Review.

PMID:
29251284
37.

Decision tree for accurate infection timing in individuals newly diagnosed with HIV-1 infection.

Verhofstede C, Fransen K, Van Den Heuvel A, Van Laethem K, Ruelle J, Vancutsem E, Stoffels K, Van den Wijngaert S, Delforge ML, Vaira D, Hebberecht L, Schauvliege M, Mortier V, Dauwe K, Callens S.

BMC Infect Dis. 2017 Nov 29;17(1):738. doi: 10.1186/s12879-017-2850-6.

38.

Diagnostic thresholds for free light chains in multiple myeloma depend on the assay used.

Bossuyt X, Delforge M, Reynders M, Dillaerts D, Sprangers B, Fostier K, Poesen K, Vercammen M.

Leukemia. 2017 Nov 20. doi: 10.1038/leu.2017.335. [Epub ahead of print]

PMID:
29151583
39.

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.

Facon T, Dimopoulos MA, Dispenzieri A, Catalano JV, Belch A, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis NJ, Banos A, Tiab M, Delforge M, Cavenagh JD, Geraldes C, Lee JJ, Chen C, Oriol A, De La Rubia J, White D, Binder D, Lu J, Anderson KC, Moreau P, Attal M, Perrot A, Arnulf B, Qiu L, Roussel M, Boyle E, Manier S, Mohty M, Avet-Loiseau H, Leleu X, Ervin-Haynes A, Chen G, Houck V, Benboubker L, Hulin C.

Blood. 2018 Jan 18;131(3):301-310. doi: 10.1182/blood-2017-07-795047. Epub 2017 Nov 17.

40.

Hepatitis E virus (HEV): seroprevalence and HEV RNA detection in subjects attending a sexually transmitted infection clinic in Brussels, Belgium.

Dauby N, Suin V, Jacques M, Abady M, VAN DEN Wijngaert S, Delforge M, DE Wit S, Libois A.

Epidemiol Infect. 2017 Dec;145(16):3370-3374. doi: 10.1017/S0950268817002412. Epub 2017 Nov 6.

PMID:
29103401
41.

Severe myoglobinuric acute kidney injury in a kidney recipient: rapid recovery after hemodialysis with the super high-flux membrane Theralite®
.

Goubella A, Gankam-Kengne F, Baudoux T, Fagnoul D, Husson C, Delforge ML, Broeders N, Nortier JL.

Clin Nephrol. 2017 Dec;88(12):359-363. doi: 10.5414/CN109020.

PMID:
28992849
42.

Blinatumomab in relapsed/refractory diffuse large B cell lymphoma.

Van Dijck R, Janssens A, Dierickx D, Delforge M, Gheysens O, Tousseyn T, Verhoef G.

Ann Hematol. 2017 Oct;96(10):1759-1762. doi: 10.1007/s00277-017-3088-5. Epub 2017 Aug 5. No abstract available.

PMID:
28779352
43.

Long-term health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma receiving lenalidomide and dexamethasone.

Vogl DT, Delforge M, Song K, Guo S, Gibson CJ, Ervin-Haynes A, Facon T.

Leuk Lymphoma. 2018 Feb;59(2):398-405. doi: 10.1080/10428194.2017.1334125. Epub 2017 Jun 22.

PMID:
28641472
44.

A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes.

Platzbecker U, Symeonidis A, Oliva EN, Goede JS, Delforge M, Mayer J, Slama B, Badre S, Gasal E, Mehta B, Franklin J.

Leukemia. 2017 Sep;31(9):1944-1950. doi: 10.1038/leu.2017.192. Epub 2017 Jun 19.

45.

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study.

Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X, Beksac M, Alsina M, Oriol A, Cavo M, Ocio EM, Mateos MV, O'Donnell EK, Vij R, Lokhorst HM, van de Donk NWCJ, Min C, Mark T, Turesson I, Hansson M, Ludwig H, Jagannath S, Delforge M, Kyriakou C, Hari P, Mellqvist U, Usmani SZ, Dytfeld D, Badros AZ, Moreau P, Kim K, Otero PR, Lee JH, Shustik C, Waller D, Chng WJ, Ozaki S, Lee JJ, de la Rubia J, Eom HS, Rosinol L, Lahuerta JJ, Sureda A, Kim JS, Durie BGM.

Leukemia. 2017 Nov;31(11):2443-2448. doi: 10.1038/leu.2017.138. Epub 2017 May 12.

PMID:
28620163
46.

Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.

Moreau P, Dimopoulos MA, Richardson PG, Siegel DS, Cavo M, Corradini P, Weisel K, Delforge M, O'Gorman P, Song K, Chen C, Bahlis N, Oriol A, Hansson M, Kaiser M, Anttila P, Raymakers R, Joao C, Cook G, Sternas L, Biyukov T, Slaughter A, Hong K, Herring J, Yu X, Zaki M, San-Miguel J.

Eur J Haematol. 2017 Sep;99(3):199-206. doi: 10.1111/ejh.12903. Epub 2017 Jun 14.

PMID:
28504846
47.

Multipotent adult progenitor cells improve the hematopoietic function in myelodysplasia.

Roobrouck VD, Wolfs E, Delforge M, Broekaert D, Chakraborty S, Sels K, Vanwelden T, Holvoet B, Lhoest L, Khurana S, Pandey S, Hoornaert C, Ponsaerts P, Struys T, Boeckx N, Vandenberghe P, Deroose CM, Verfaillie CM.

Cytotherapy. 2017 Jun;19(6):744-755. doi: 10.1016/j.jcyt.2017.03.009.

48.

Low frequency mutations in ribosomal proteins RPL10 and RPL5 in multiple myeloma.

Hofman IJF, Patchett S, van Duin M, Geerdens E, Verbeeck J, Michaux L, Delforge M, Sonneveld P, Johnson AW, De Keersmaecker K.

Haematologica. 2017 Aug;102(8):e317-e320. doi: 10.3324/haematol.2016.162198. Epub 2017 Apr 20. No abstract available.

49.

Performance evaluation of direct fluorescent antibody, Focus Diagnostics Simplexa™ Flu A/B & RSV and multi-parameter customized respiratory Taqman® array card in immunocompromised patients.

Steensels D, Reynders M, Descheemaeker P, Curran MD, Jacobs F, Denis O, Delforge ML, Montesinos I.

J Virol Methods. 2017 Jul;245:61-65. doi: 10.1016/j.jviromet.2017.03.013. Epub 2017 Mar 30.

PMID:
28365410
50.

Presence of Cytomegalovirus in urine and blood of pregnant women with primary infection might be associated with fetal infection.

Delforge ML, Costa E, Brancart F, Goldman D, Montesinos I, Zaytouni S, Marchant A, Donner C.

J Clin Virol. 2017 May;90:14-17. doi: 10.1016/j.jcv.2017.03.004. Epub 2017 Mar 7.

PMID:
28319846

Supplemental Content

Loading ...
Support Center